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Abstract
N-cadherin seems to promote cell migration and invasion in many types of cancers. The object of this study is recognition of 
the possible role of N-cadherin and selected downstream protein kinases: PI3K, ERK1/2, and mTOR in cell invasion in malig-
nant melanoma. Melanoma cells were transfected with the small interfering RNA (siRNA) that targets human N–cadherin 
gene (CDH2). Inhibitors LY294002 (PI3K), U0126 (ERK1/2), and everolimus (mTOR) were used to inhibit selected kinases 
of signalling pathways. In vitro cell invasion was studied using Matrigel and an analysis of matrix metalloproteinases MMP-2 
and MMP-9 activity by gelatinase zymogram assay. Treatment of melanoma cell with either siRNA against N-cadherin or 
protein kinase inhibitors led to significantly decreased MMPs expression and activity, as well as diminished invasion. Both 
the current and the former results suggest that activation of PI3/AKT, mTOR, and ERK kinase, following N-cadherin expres-
sion, contributes not only to increased proliferation but also invasive potential of melanoma cells. The results also indicate 
that N-cadherin, as well as the studied kinases, should be considered as a potential target in melanoma therapy.
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Introduction
It is becoming ever clearer that integration of signals trig-
gered by cell–cell interactions, cell–matrix signalling, and 
growth factor signalling plays a crucial role in cellular 
behaviour. Cadherins have been implicated in a number of 
signalling pathways that stimulate cellular behaviour. They 
are also of key importance for embryo compaction [1], cell 
intercalation [2, 3], and cell sorting [4]. Furthermore, cad-
herins with associated protein-mediated cell–cell adhesion 
promote a unique cytoskeletal structure that supplies adhe-
sive strength [5–9]. Interest in cadherins has grown since the 
late 1980s, when they were found to be linked with cancer 
progression and other diseases.
Human melanocytes express both E-cadherin and P-cad-
herin. E-cadherin is responsible for adhesion of melanocytes 
to keratinocytes. Melanocytes embedded in the basal layer 
of epidermis interact with keratinocytes through E-cadherin, 
which in effect regulates their growth [10]. Pathologic 
changes leading to growth of malignant melanomas disturb 
the delicate homeostatic balance between melanocytes and 
keratinocytes and can lead to altered cell–cell adhesion and 
cell–cell connections. In majority of epithelial cancers, loss 
of E-cadherin (CDH1), P-cadherin (CDH3) or both during 
tumour progression results in an increased expression of the 
mesenchymal cadherin, i.e. N-cadherin, with a significant 
change in the adhesive properties of cancer cells, as they lose 
their affinity for epithelial neighbours in favour of stromal 
cells [5, 11–15].
One of the first and most important steps in the meta-
static cascade is the loss of cell–cell and cell–matrix inter-
actions. N-cadherin, a crucial factor of homotypic and het-
erotypic cell–cell interactions, might play a central role in 
the metastasis.
It was shown that in various cancer cells expression of 
N-cadherin is associated with cell migration as it induces 
cells’ motility in many types of cancers such as breast, pros-
tate, and gastric cancer. Since overexpression of N-cadherin 
increases migration and invasion of cells without reducing 
the level of E-cadherin, these results suggest that it is the 
presence of N-cadherin rather than the absence of E-cad-
herin that is instrumental for increased cell invasiveness 
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[16]. Therefore, strict regulation of N-cadherin expression 
is essential in normal epithelial cell function [16].
Degradation of basement membranes and stromal extra-
cellular matrix (ECM) is crucial for invasion and metas-
tasis of malignant cells. Extracellular matrix degradation 
is initiated by proteinases secreted by different cell types 
participating in tumour cell invasion, and increased expres-
sion of every known class of proteinases has been linked to 
malignancy and invasion of tumour cells [17]. Gelatinase A 
(MMP-2, 72kDa gelatinase) is expressed in a variety of nor-
mal and transformed cells, including fibroblasts, keratino-
cytes, endothelial cells, and chondrocytes. Gelatinase B 
(MMP-9, 92kDa gelatinase) is produced by keratinocytes, 
monocytes, macrophages, and many malignant cells. High 
levels of MMP-9 were detected in breast, colorectal, and 
gastric cancers. The possibility of using MMP-9 as a marker 
of skin melanoma vertical growth phase (VGP) has been 
suggested [18].
In addition to induction of degradation of extracellular 
matrix components, MMP-9 is involved in regulation of the 
basic biological processes of: apoptosis, proliferation, and 
differentiation [19, 20].
The role of N-cadherin in cell differentiation, cancer 
transformation, and invasion has also been documented [11, 
21] with some of these functions, most probably depending 
on the activation of intracellular signal transduction cascades 
[22]. However, neither the mechanism by which N-cadherin 
regulates entry into the cell cycle nor its migratory charac-
teristics have yet been fully elucidated.
Therefore, following our earlier report on the role of 
N-cadherin in melanoma proliferation [23], we sought to 
look at the possible initiative role of this adhesion molecule 
on cancer cell migration and invasive potential.
Materials and methods
Cell culture
Human melanoma cell lines: WM793 (VGP—vertical 
growth phase); Lu1205 (metastatic; biopsy taken from the 
lung; selection in mice; a culture from the primary site 
(sternum area) from the same donor as WM793. WM115 
(VGP—vertical growth phase) and WM266-4 (metastatic, 
skin) were cultured in RPMI-1640 medium supplemented 
with 10% foetal bovine serum and antibiotics: penicillin, 
streptomycin. Cells were incubated at  37◦C in a humidified 
atmosphere of 5%  CO2 in air. Cells were treated with inhibi-
tors of: 1/PI3K—LY294002 (Cell Signalling TM) at 20 μM 
concentration, 2/ERK1/2—U0126 (Cell Signalling TM) at 
10 μM concentration, and 3/mTOR—everolimus (Selleck) at 
5 nM concentration. The incubation time of melanoma cells 
with inhibitors was 24 and 48 h. Cells were obtained from 
the ESTDAB Melanoma Cell Bank (Tubingen, Germany).
siRNA transfection of melanoma cells
Melanoma cells were grown until 60% confluence was 
reached, and then transfected using Oligofectamine reagent 
(Invitrogen), in keeping with the manufacturer’s protocol, 
previously described [23] 21 bp double-stranded siRNA 
molecules specifically targeting for the N-cadherin: siRNA 
CDH2 (target sequence 5′-AAA GTG GCA AGT GGC AGT 
AAA-3′—nucleotides 798–818; NM001792)—gener-
ated in vitro transcription (SilencerTM siRNA Construc-
tion Kit (Ambion)) and commercially available (Ambion 
ID#S27773) or a control non-silencing sequence (Ambion 
ID#4390843) [23]. The effects that RNA interference had on 
expression of CDH2 mRNA and protein were determined by 
reverse transcription-PCR (RT-PCR) and Western immuno-
blotting, respectively, described previously [23].
WM793, WM115, and WM266-4 cells were transfected 
with 50 nM, and Lu1205 cells with 100 nM siRNA. Medium 
was replaced 24 h later with a fresh one, and cells were 
grown for an additional 24 to 48 h period (48 or 72 h post-
tansfection) prior to further analysis [23].
Cell migration and invasion assay
Cell invasion assays were performed using conventional 
Boyden transwell methods in keeping with the manufac-
turer’s protocol (BD BioCoat™ FluoroBlok Invasion System 
No. 354166). Melanoma cell migration was studied with the 
use of FluoroBlok Inserts System No. 351157. Quantita-
tion of invasion was achieved by post-invasion cell labelling 
with Calcein AM (Fluka), and measuring the fluorescence 
of invading cell samples at excitation/emission wavelengths 
of 485/530 nm sensitivity 100 on a plate reader (BIO-TEK).
Zymography
Melanoma cells from primary (WM793, WM115) and meta-
static sites (Lu1205, WM266-4) were grown as monoculture 
for various periods of time (24, 48 h). Serum-free, condi-
tioned media were collected, and activity of the metallopro-
teinases: MMP-2 and MMP-9 was analysed using gelatin 
zymography.
Gels were prepared in the presence of 0.1% gelatin 
(Sigma) in non-reducing conditions. Proteins were loaded 
per well and separated with the use 4.5% stacking and 10% 
separation gel in a 4 h run. Following electrophoresis, the 
gel was washed two times for 30 min in 2.5% TritonX-100.
The gel was intubated at 37 °C for 48 h in buffer (50 mM 
Tris pH 7.5; 10 mM  CaCl2; 0.15 mM NaCl).
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Then the gel was stained in a solution containing 1% 
Coomasie blue R250 in 50% methanol and 10% acetic acid 
for 1 h. Gelatinolytic activity was observed as clear areas 
in the gel.
Densitometry analysis
Densitometry analyses of gelatinolytic activities of metal-
loproteinases MMP-2 and MMP-9 were performed on raw 
volume (sum of intensities of bound—volume calculated 
from the area of the peak) using SynGene Gene Tools ver-
sion 4.03.0 (Synoptics Ltd Beacon House, Nuffield Road 
Cambridge, CB4 1TF, UK).
Cytotoxicity assay
Cytotoxicity of N-cadherin siRNA (100 nM), PI3K inhibi-
tor—LY294002 (20  μM), ERK1/2 inhibitor—U0126 
(10 μM), and everolimus (5 nM) mTOR inhibitor assay 
was determined using Cytotoxicity Detection Kit LDH, 
Roche, Germany. In all examined melanoma cell lines, both 
N-cadherin siRNA and inhibitors: everolimus, LY294002, 
U0126 showed no cytotoxicity effect when tested in a cul-
ture medium at the time of 72 h. LDH activity in the culture 
medium in no case exceeded 3%.
Western blot analysis
Preparation of samples for electrophoresis and western blot 
analysis was made as described previously [23]. The fol-
lowing antibodies: MMP-2 (AV20016, SIGMA), MMP-9 
(IM09L, Merck Millipore), N-cadherin (610920, BD Trans-
duction Laboratories) and β-actin (A2228, SIGMA) were 
used.
Statistics
Cell invasion data were calculated from mean values of 
repeated experiments. Statistical analyses were performed 
using one-way ANOVA with post hoc Tukey test (Statistica 
12.0 StatSoft); asterisk (*) indicates a significant differ-
ence p < 0.005, and double asterisk (**) indicates a signifi-
cant difference p < 0.0005.
Results
N‑cadherin regulates cell invasion
The study on the role of N-cadherin in migration and inva-
sion of melanoma cells was performed using conventional 
Boyden transwell methods. All tested melanoma cell lines 
manifested the ability for cellular migration as a capacity 
to chemotaxis. Cells’ invasion after 48-h knock-down of 
N-cadherin compared with control (non-specific siRNA) or 
non-treated cells was measured.
N-cadherin siRNA-transfected cells showed reduction 
in invasion by 20–25% when compared with control cells 
(Fig. 1). The effect was observed for primary WM793 and 
WM115, as well as metastatic Lu1205 and WM266-4 cell 
lines. The most inhibition was, noticed in case of WM793 
(VGP) and WM266-4, invasion of which was reduced 
by: 25% (p < 0.0005) and 23% (p < 0.0005), respectively 
(Fig. 1).
Separate use of inhibitors: U0126 (ERK1/2) or everolimus 
(mTOR) reduced melanoma cell invasion by approximately 
21–25% (p < 0.005), whereas treatment with LY294002 
(PI3K) reduced it by only about 15% (p < 0.005). Treatment 
of melanoma cells with combination of U0126 (ERK1/2) 
and LY294002 (PI3K) inhibitors decreased it by about 
25% (p < 0.005). Applications of a combination of siRNA 
for N-cadherin and U126 (ERK1/2) inhibitor resulted in a 
reduction of invasiveness of cells by about 38% (p < 0.0005) 
in Lu1205 cell line, and similar response was observed in 
the case of a combination of siRNA for N-cadherin with 
everolimus (mTOR) inhibitor (Fig. 1).
N‑cadherin regulates gelatinolytic activities 
of the metalloproteinases MMP‑2 and MMP‑9
siRNA for the N-cadherin (siRNACDH2) effectively 
reduced the expression of N-cadherin (Fig. 2a). In a previ-
ous work, [23] described in detail the effect of silencing 
N-cadherin on melanoma cells.
The invasive ability of cancer cells can be regulated 
through expression of zinc-dependent endopeptidases, 
MMPs. Metalloproteinases 2 and 9 were identified in mela-
noma cell lines through western blot analysis (Fig. 2b). High 
protein levels of metalloproteinase MMP-2 were found in all 
examined melanoma cell lines. In the case of metalloprotein-
ase MMP-9, a much lower protein level was observed except 
in Lu1205 cell line (Fig. 2b).
Therefore, activities of MMP-2 and MMP-9 were stud-
ied in both the primary (WM793, WM115) and metastatic 
(Lu1205, WM266-4) cells lines. MMP-9 activity was always 
much lower than that of MMP-2, except for the Lu1205 
cells. Both monomeric and dimeric forms of MMP-9 were 
observed in all tested cell lines except Lu1205 (Fig. 2c).
Zymography used to measure the activity of metallo-
proteinases in melanoma cells revealed a significant differ-
ence between MMP-2 and MMP-9 activities in N-cadherin 
knocked-down cells in all tested cell lines in comparison 
with untreated ones. The greatest decreases in MMP-2 activ-
ity were observed after 48-h treatment. These reached about 
47% in the Lu1205 cells, and about 40% in WM793 line. 
The smallest decreases, at the level of 12%, were observed 
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Fig. 1  The effect of N-cadherin silencing by siRNA and protein 
kinase inhibitors on melanoma cell invasion “in vitro”. Cell inva-
sion assay through Matrigel-coated Boyden chamber. Histogram 
shows the quantification of cell invasion. Values are expressed as 
mean  ±  standard deviation in 4 wells in two independent experi-
ments. All results are presented as experimental mean values which 
were compared using one-way ANOVA with the Tukey’s post hoc 
test (Statistica ver. 12, StatSoft,); asterisk (*) indicates a significant 
difference: *p < 0.005, **p < 0.0005
Fig. 2  N-cadherin regulates and MMPs activity. a The effect of 
N-cadherin silencing in melanoma cells. b Identification of the met-
alloproteinases 2 and 9 in melanoma cell lines by western blot anal-
ysis. c The effect of N-cadherin silencing on gelatinolytic activities 
of MMP-2 and MMP-9 in melanoma cells. d Densitometric analysis 
of MMP-2 and MMP-9 activity. Raw volume (sum of intensities of 
bound—volume calculated from the area of the peak)
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in WM115. In the case of MMP-9, decreases of activity 
reached 62 and 52% of their initial values in Lu1205 and 
WM793 cells, respectively. Summary of the results of densi-
tometry analysis of the activity of MMP-2 and MMP-9 after 
N-cadherin knock-down is presented in (Fig. 2d).
We sought to check if the decreases in MMPs activities 
caused by N-cadherin silencing may be strengthened by 
additional inhibition treatment with selected signal kinases 
inhibitors.
The largest decreases in the activities of metallopro-
teinases, particularly in MMP-2, were observed in the 
case of 48-h treatment of cells with combination of siRNA 
for N-cadherin and PI3K inhibitor—LY294002 (Fig. 3a, 
b). With shorter (24 h) incubation time, best results were 
achieved with application of combination of siRNA for 
N-cadherin and inhibitor U0126 (ERK1/2). High efficiency 
of MMPs inhibition was also reached with the combination 
of siRNA for N-cadherin and inhibitor everolimus (mTOR), 
regardless of incubation time. Use of a single inhibitor gave 
similar results to N-cadherin gene silencing, but much less 
promising than in the case of combinations of inhibitors and 
siRNA for N-cadherin (Fig. 3a, b).
The activity of MMP-9 was much lower than that of 
MMP-2, with the exception of Lu1205. As in the case of 
MMP-2, the greatest decreases in MMP-9 activity were 
observed when using a combination of siRNA for N-cad-
herin and PI3K inhibitor—LY294002. Similar results were 
observed for both metalloproteinases: MMP-2 and MMP-9 
after application of mTOR inhibitors—everolimus. Mela-
noma cells react differently to MEK kinase inhibitor. Small 
increase in the activity of metalloproteinases in the two cell 
lines: WM115 (VGP) and WM 266-4 (from the same source) 
was observed.
Figure 3a, b illustrates the results of densitometry com-
parison of MMP-2 and MMP-9 activity after knock-down of 
N-cadherin and treating with U0126 (ERK1/2), LY294002 
(PI3K) and everolimus (mTOR) inhibitors.
Discussion
It has been previously demonstrated that N-cadherin had 
significant effect on cell signalling, cell cycle regulation, 
and, in consequence, proliferation of melanoma cells, as the 
use of siRNA against N-cadherin led to significant reduction 
in number of such treated cancer cells [23].
The current study confirmed that melanoma cells trans-
fected with N-cadherin specific siRNA successfully and 
transiently decreased its expression at mRNA and protein 
levels. This resulted in inhibition of metalloproteinase 2 and 
9 activities, as well as reduced cell invasion.
In various cancer cells, high expression of N-cadherin 
is associated with activation of cell motility. Expression of 
N-cadherin induces cell migration of cancer such as breast, 
prostate, gastric, and melanoma [21, 24–27]. Furthermore, 
the E-cadherin to N-cadherin switch is often found in 
aggressive cancers [28]. The up-regulation of N-cadherin in 
aggressive carcinomas suggests that the level of N-cadherin 
expression is a critical step for cancer cell invasion.
Melanoma cell invasion
The results of the study on the effects of N-cadherin knock-
down on cell invasion confirm the role of this adhesion mol-
ecule in the process of invasion of melanoma cells. In all 
tested melanoma cell lines, a statistically significant decrease 
in the number of invading cells in the range between 20 and 
25% was observed. Furthermore, impact of protein kinase 
inhibitors: LY294002, U126, everolimus, and combination 
of siRNA for N-cadherin and protein kinase inhibitors on 
the process of melanoma cell invasion reported here sug-
gests involvement of all three kinases in N-cadherin-initiated 
signalling. Simultaneous administration of any of protein 
kinase inhibitors and siRNA for N-cadherin resulted in a 
decrease of approximately 30%, whereas with the use of 
a combination of siRNA for N-cadherin and ERK MAPK, 
pathway inhibitors-U126 diminished cells invasion by up 
to 38%.
MMPs in tumour progression
MMPs play an important role in many biological and patho-
logical processes. Uncontrolled, activity of metalloprotein-
ases may well lead to development of many diseases such as 
arthritis, atherosclerosis, aneurysms, nephritis, tissue ulcers 
or fibrosis, and cancer [29]. The MMPs have been present in 
the discussion on cancer for more than 40 years, being over-
expressed in a large range of malignant tumours in response 
to oncogenic transformation, and activation of cytokines, 
several growth and angiogenic factors [30].
Initial observations on the role of MMPs in the cancer 
biology have suggested that the ability of tumour cells to 
metastasize correlates with increased levels of metallopro-
teinase activity. Elevated levels of gelatinases, MMP-2 and 
MMP-9, are often observed in malignant cancers. Among 
human melanoma cells, MMP-2 and MMP-9 have attracted 
attention in the recent years, especially with regard to cuta-
neous, eye, and oral melanomas [30]. Expression of MMP-2 
has frequently been associated with malignant progression 
and poor prognosis [31]. Particularly, high levels of MMP-2 
were observed in WM793 melanoma cell line from the pri-
mary VGP.
Results of studies using tissue microarray, immunohisto-
chemistry of melanoma biopsies of primary and metastatic 
lesions, as well as nevi, confirmed that MMP-2 is predic-
tive of primary and metastatic stages [30]. High MMP-2 
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expression in primary lesion contributes to invasiveness of 
primary tumour cells, leading to metastases and poor sur-
vival outcomes [32].
Similarly to other publications [33], this study showed 
a high level of the MMP-2 activity in all tested melanoma 
cell lines.
Fig. 3  The effect of N-cadherin silencing and protein kinase inhibi-
tors on gelatinolytic activities of MMP-2 and MMP-9 in melanoma 
cells: a Lu1205 and WM793. b WM266-4 and WM115. Densito-
metric analysis of MMP-2 and MMP-9 activity. Raw volume (sum of 
intensities of bound—volume calculated from the area of the peak)
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The second gelatinase MMP-9 proved to be much less 
active than MMP-2, except for the Lu1205 from metastatic 
cell line, where activity of MMP-9 was at a high level. Here, 
monomeric and dimeric forms of MMP-9 were detected in 
all tested lines except for Lu1205. MMP-9 also exists as a 
monomeric and homodimeric molecule, in both its latent and 
active forms. Both monomeric and dimeric forms of MMP-9 
have been identified in biological fluids and tissues, in a 
variety of normal and neoplastic cells [34]. Dimerization or 
multimerization is mediated by the carboxyterminal domains 
of MMP-9 and occurs intracellularly [34]. The functional 
biological role of the MMP-9 dimer has not yet been elu-
cidated; however, dimerization significantly decreases the 
activation rate of pro-MMP-9 by stromelysin (MMP-3) [34].
The herein reported significant decrease in MMP-2 and 
MMP-9 protein levels and activities that was observed after 
knock-down of N-cadherin remains in agreement with the 
view on the importance of this adhesion molecule for activa-
tion of matrix metalloproteinases, and in effect stimulation 
of invasion and metastasis. The largest decreases of MMP-2 
activity were observed in the Lu1205 and line WM793 (by 
about 47 and 40%, respectively). Concurrently, MMP-9 
activity in the cell lines dropped by about 62 and 52%, 
respectively.
Decreases of MMP-2 and MMP-9 activities were also 
observed upon using a combination of siRNA for N-cadherin 
and protein kinases inhibitors: LY294002 (PI3K), U126 
(ERK1/2), and everolimus (mTOR). The largest decrease 
in activity of metalloproteinase, MMP-2 in particular, was 
observed upon using a combination of siRNA for N-cadherin 
and PI3K inhibitor LY294002 after 48-h treatment, while at 
shorter incubation time (24 h) application of a combination 
of siRNA for N-cadherin and inhibitor U0126 produced best 
results. Using the combination of siRNA for N-cadherin and 
inhibitor of mTOR—everolimus gave similar results regard-
less of the incubation time.
Hazan et al. [21] suggested that N-cadherin functionally 
interacts with the FGF receptor, causing sustained down-
stream signalling by PI3K, and through MAPK-ERK pro-
motes cell survival, migration, and invasion. Stabilization 
of FGF-1 receptor by N-cadherin, followed by MAPK-ERK 
activation, may result in increased transcription of the extra-
cellular matrix-degrading enzyme MMP-9, and hence, an 
increased cellular invasiveness. The FGF-1 may interact 
with the fourth extracellular domain (EC4) of N-cadherin 
based on the fact that transfer of EC4 domain from N-cad-
herin onto E-cadherin reconstituted the invasive function 
of N-cadherin [21]. Other authors suggest the role of the 
cytoplasmic domain of N-cadherin [35, 36] and soluble 
N-cadherin domain in regulating cell migration [37].
Current results demonstrate the important role of 
N-cadherin in melanoma cell invasion. In light of our for-
mer studies, where observed was a significant reduction in 
melanoma cell proliferation in effect of N-cadherin silenc-
ing, the hypothesis that MMP-9 expression and cellular 
invasion are governed by at least two, but possibly more, 
distinct intracellular signalling pathways when stimulated 
by N-cadherin-FGFR signalling [21], seems to be a sound 
one.
Melanoma cells react differently to the MEK kinase 
inhibitors, as Ferguson et  al. [22] observed a slight 
increase in the activity of MMP-2 in the use of ERK1/2 
inhibitor—U126. Preclinical data presented by Catalanotti 
et al. [38] suggest that patients with B-RAF mutant mela-
nomas and PI3K/AKT pathway activation are less sensi-
tive to MEK inhibition. 50% of melanoma cases showed 
presence of B-RAF mutation. For example, all studied cell 
lines exhibit B-RAF mutations: Lu1205 and WM793—
V600E, WM115 and WM266-4 V600D.
The need for search of effective multitargeted therapies 
or broad spectrum approach to cancer treatment [39] fully 
justifies the attempts to recognize the effect of collective 
inhibition of the activity of N-cadherin and some crucial 
signal transducers, such as protein kinases: PI3K, ERK, 
and mTOR. The conducted studies demonstrated that inhi-
bition of N-cadherin or one of kinases produces less sat-
isfactory effects than parallel inhibition of at least two of 
them, as shown here and formerly [23]. These results many 
open up new avenues for developing low-dose anticancer 
therapies, which would allow to reduce the negative side 
effects of the high doses often administered in case of 
individual anticancer agent [40].
Particularly promising are the results with regard to the 
decrease in melanoma cells invasiveness after N-cadherin 
gene silencing and the use of everolimus inhibitor of the 
mTOR pathway. everolimus is a low-toxicity drug that has 
been used as an immunosuppressant in organ transplant 
patients, in particular in cancer-related cases for several 
years [41]. In recent years, use of everolimus and other 
inhibitors of the mTOR pathway for antitumor therapy has 
attracted some interest [41, 42]. The fact that their inhibi-
tory effect may be significantly enhanced by simultaneous 
use of siRNA for N-cadherin may be worth considering 
as a potentially new approach to effective treatment of 
melanoma.
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